CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Capricor Therapeutics Inc (CAPR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with multiple buy ratings and increasing price targets, a bullish technical setup, and significant potential catalysts such as the upcoming FDA decision for Deramiocel. Despite weak financial performance in the last quarter, the long-term growth prospects tied to Deramiocel's approval and market potential outweigh the short-term negatives.
The technical indicators are bullish. The MACD is above 0 and positively contracting, suggesting a continuation of upward momentum. The RSI is neutral at 71.283, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of 35.307, with support at 32.602. This indicates a favorable entry point for long-term investors.
FDA decision on Deramiocel expected by August 22, with strong Phase 3 data supporting approval.
Analysts have raised price targets significantly, with targets ranging from $41 to $
Retail sentiment has shifted from bearish to bullish, with expectations of the stock exceeding $75 upon FDA approval.
Potential influence of former VP Houman Hemmati being considered for an FDA role, which could benefit Capricor's approval prospects.
Weak financial performance in Q4 2025, with revenue dropping to 0 and net income at -$30.17M.
Gross margin also dropped to 0, indicating no profitability in the last quarter.
No significant hedge fund or insider trading activity, suggesting a lack of institutional conviction in the short term.
In Q4 2025, Capricor's revenue dropped to 0 (-100% YoY), and gross margin also fell to 0. However, net income improved to -$30.17M (+323.95% YoY), and EPS increased to -0.62 (+287.50% YoY). While financials remain weak, the company is in a pre-revenue stage, focusing on the development and approval of Deramiocel.
Analysts are highly bullish on CAPR, with multiple buy ratings and raised price targets. Roth Capital raised its target to $43, B. Riley to $63, Alliance Global to $51, and Piper Sandler to $58. Analysts cite confidence in Deramiocel's approval, multi-billion revenue potential, and durable demand dynamics as key drivers for the stock's upside.
